StockScan › Stocks › ALLK
Biotechnology
ALLK
3.28
  Price2.82%   +0.0900
(Pre-market: .00 -3.28 -100.00%)
KEY STATS
Previous Close:
$3.19
Market Cap:
$179.67M
24h Volume:
775.50K
1D Range:
$3.17 - $3.31
52W Range:
$2.77 - $112.87
Primary Exchange:
COMPANY PROFILE
NameNameAllakos Inc.
SectorHealthcare (1253)
IndustryBiotechnology (742)
Weballakos.com
Phone650-597-5002
Employee51
Latest SEC Filings
ALLK's Discussions on Twitter
75 Shoreway Road, Suite A, San Carlos, CA, United States (94070)
News New Options Data Financials Holders Transactions Discussions Predictions
May-09-22 06:38AM A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall StreetBenzinga
05:07AM 5 Stocks To Watch For May 9, 2022Benzinga
May-06-22 04:05AM Allakos Provides Business Update and Reports First Quarter 2022 Financial ResultsGlobeNewswire Inc.
Mar-07-22 10:39AM Why Allakos Stock Sank 17.3% in FebruaryThe Motley Fool
Mar-01-22 04:05AM Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewswire Inc.
Feb-21-22 09:53AM Allakos (ALLK) to Report Q4 Earnings: What's in the Cards?Zacks Investment Research
Feb-16-22 03:15AM Analyst Ratings For AllakosBenzinga
Feb-07-22 09:01AM 12 biotech stocks to consider buying now as prospects for the sector brighten this yearMarketWatch
Feb-06-22 04:53AM 12 biotech stocks to consider buying now as prospects for the sector brighten this yearMarketWatch
Jan-06-22 08:17AM Why Allakos Stock Plummeted 87.5% in the Last Month of 2021The Motley Fool
Dec-26-21 09:53AM The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of YearBenzinga
Dec-22-21 10:41AM Why Allakos Stock Is Crashing TodayThe Motley Fool
09:07AM Tesla's Rising, but This Nasdaq Biotech Stock Got Absolutely Crushed WednesdayThe Motley Fool
Dec-22-21 07:41AM The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For TakedaBenzinga
Dec-21-21 07:15AM Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal DiseasesGlobeNewswire Inc.
Nov-19-21 08:40AM Do Options Traders Know Something About Allakos (ALLK) Stock We Don't?Zacks Investment Research
About Allakos Inc.
Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in San Carlos, California.
List of SPAC Stocks List of EV Stocks and Related Stocks Top 100 popular stocks on Robinhood List of Marijuana Stocks
Open in Yahoo | Open in Google | Open in Finviz
Cap:    |  Volume (24h):